A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma

Li, Wentao; Zou, Jiaxuan; Ren, Rijun; Liu, Jingping; Zhang, Gentang; Wang, Maokai

doi:10.1177/1533033821992084

Cited by 13 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a precursor of regulatory peptide, the relationship between CHGB and tumor is not clear. However, CHGB was suggested to be an immune-related signature for low-grade glioma ( Liu et al, 2021 ) and head and neck squamous cell carcinoma ( Zhang et al, 2021 ). Previous studies also experimentally demonstrated that an abnormal expression of CHGB was associated with aggressive VHL-associated pancreatic neuroendocrine tumors (validated by immunohistochemistry) ( Weisbrod et al, 2013 ), pancreatic cancer (validated by qPCR) ( Jia-Sheng Xu et al, 2020 ), and small cell lung cancer (validated by immunoblotting and qPCR) ( Moss et al, 2009 ).…”

Section: Discussionmentioning

confidence: 99%

Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer

Cao

Ba³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Colon cancer is a common malignant tumor with poor prognosis. The aim of this study is to explore the immune-related prognostic signatures and the tumor immune microenvironment of colon cancer.Methods: The mRNA expression data of TCGA-COAD from the UCSC Xena platform and the list of immune-related genes (IRGs) from the ImmPort database were used to identify immune-related differentially expressed genes (DEGs). Then, we constructed an immune-related risk score prognostic model and validated its predictive performance in the test dataset, the whole dataset, and two independent GEO datasets. In addition, we explored the differences in tumor-infiltrating immune cell types, tumor mutation burden (TMB), microsatellite status, and expression levels of immune checkpoints and their ligands between the high-risk and low-risk score groups. Moreover, the potential value of the identified immune-related signature with respect to immunotherapy was investigated based on an immunotherapeutic cohort (Imvigor210) treated with an anti-PD-L1 agent.Results: Seven immune-related DEGs were identified as prognostic signatures. The areas under the curves (AUCs) of the constructed risk score model for overall survival (OS) were calculated (training dataset: 0.780 at 3 years, 0.801 at 4 years, and 0.766 at 5 years; test dataset: 0.642 at 3 years, 0.647 at 4 years, and 0.629 at 5 years; and the whole dataset: 0.642 at 3 years, 0.647 at 4 years, and 0.629 at 5 years). In the high-risk score group of the whole dataset, patients had worse OS, higher TMN stages, advanced pathological stages, and a higher TP53 mutation rate (p < 0.05). In addition, a high level of resting NK cells or M0 macrophages, and high TMB were significantly related to poor OS (p < 0.05). Also, we observed that high-risk score patients had a high expression level of PD-L1, PD-1, and CTLA-4 (p < 0.05). The patients with high-risk scores demonstrated worse prognosis than those with low-risk scores in multiple datasets (GSE39582: p = 0.0023; GSE17536: p = 0.0008; immunotherapeutic cohort without platinum treatment: p = 0.0014; immunotherapeutic cohort with platinum treatment: p = 0.0027).Conclusion: We developed a robust immune-related prognostic signature that performed great in multiple cohorts and explored the characteristics of the tumor immune microenvironment of colon cancer patients, which may give suggestions for the prognosis and immunotherapy in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer

Cao

Ba³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…GWAS have identified DISP2 -related risk loci for lung cancer, as well as for diverticular disease (Schafmayer et al 2019 ; Kachuri et al 2020 ). Recently, DISP2 was found downregulated in low grade glioma, as well as in an esophageal cancer cell line (Cai et al 2015 ; Liu et al 2021 ), suggesting a putative role as a tumor-suppressor protein. Importantly, DISP2 -associated risk loci have been associated with impaired brain developmental patterns (Cai et al 2014 ) and with altered cognitive functions (Davies et al 2018 ; Lee et al 2018 ; Savage et al 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Localization Pattern of Dispatched Homolog 2 (DISP2) in the Central and Enteric Nervous System

et al. 2023

View full text Add to dashboard Cite

Dispatched homolog (DISP) proteins have been implicated in the regulation of hedgehog signaling during embryologic development. Although DISP2 has recently been associated with neuronal development and control of cognitive functions, its localization pattern in the mammalian central and peripheral nervous system has not yet been investigated. In this study, the Disp2 expression profile was assessed in human tissues from publicly available transcriptomic datasets. The DISP2 localization pattern was further characterized in the human and rat central nervous system (CNS), as well as within the colonic enteric nervous system (ENS) using dual-label immunohistochemistry. Colocalization of DISP2 with neuronal and glial markers was additionally analyzed in murine primary ENS culture. At transcriptomic level, DISP2 expression was predominant in neuronal cell types of the CNS and ENS. DISP2 immunoreactivity was mainly located within PGP9.5-positive neurons rather than in S100-positive glial cells throughout the nervous system. Investigation of human and rat brain tissues, colonic specimens, and murine ENS primary cultures revealed that DISP2 was located in neuronal cell somata, as well as along neuronal processes both in the human and murine CNS and ENS. Our results indicate that DISP2 is prominently localized within neuronal cells of the CNS and ENS and support putative functions of DISP2 in these tissues.

show abstract

“…Furthermore, the predictive value of these genes for the overall survival of LGG patients was investigated. Previous efforts have focused on the expression of long non-coding RNAs ( Reon et al, 2016 ) or prognostic biomarkers ( Liu et al, 2021b ) in LGGs. To the authors’ knowledge, the present study is the first comprehensive and updated study, where a massive amount of data derived from three major resources was utilized towards the identification of candidate diagnostic and prognostic markers in LGG.…”

Section: Introductionmentioning

confidence: 99%

An in silico approach to the identification of diagnostic and prognostic markers in low-grade gliomas

Özbek

Toy

Oktay

et al. 2023

PeerJ

View full text Add to dashboard Cite

Low-grade gliomas (LGG) are central nervous system Grade I tumors, and as they progress they are becoming one of the deadliest brain tumors. There is still great need for timely and accurate diagnosis and prognosis of LGG. Herein, we aimed to identify diagnostic and prognostic biomarkers associated with LGG, by employing diverse computational approaches. For this purpose, differential gene expression analysis on high-throughput transcriptomics data of LGG versus corresponding healthy brain tissue, derived from TCGA and GTEx, respectively, was performed. Weighted gene co-expression network analysis of the detected differentially expressed genes was carried out in order to identify modules of co-expressed genes significantly correlated with LGG clinical traits. The genes comprising these modules were further used to construct gene co-expression and protein-protein interaction networks. Based on the network analyses, we derived a consensus of eighteen hub genes, namely, CD74, CD86, CDC25A, CYBB, HLA-DMA, ITGB2, KIF11, KIFC1, LAPTM5, LMNB1, MKI67, NCKAP1L, NUSAP1, SLC7A7, TBXAS1, TOP2A, TYROBP, and WDFY4. All detected hub genes were up-regulated in LGG, and were also associated with unfavorable prognosis in LGG patients. The findings of this study could be applicable in the clinical setting for diagnosing and monitoring LGG.

show abstract

A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma

Cited by 13 publications

References 40 publications

Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer

Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer

Localization Pattern of Dispatched Homolog 2 (DISP2) in the Central and Enteric Nervous System

An in silico approach to the identification of diagnostic and prognostic markers in low-grade gliomas

Contact Info

Product

Resources

About